• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029

    4/25/24 8:01:00 AM ET
    $DNA
    $HCAT
    $MSFT
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology
    Get the next $DNA alert in real time by email

    USA News Group Commentary

    VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), and Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

    Recently, Avant Technologies Inc. (OTC:AVAI) strengthened its AI-powered healthcare offerings by acquiring Wired-4-Health, a company specializing in healthcare technology and data services. This addition supports Avant's goal to create the first supercomputing network in the country. This network will offer big data and AI software companies a quicker, more potent, and more affordable computing infrastructure.

    "Our strategy behind this acquisition was to enable Avant to deliver best-in-class data and system interoperability support services to the healthcare and life sciences sectors powered by AvantAI® and our high-density compute capabilities," said Tim Lantz, CEO of Avant Technologies. "At the same time, this exciting combination significantly strengthens our financial profile, offers massive commercial growth opportunities in one of Avant's largest target markets, and bolsters our internal customer support and R&D capabilities."

    The goal of this deal is to bring together Avant Technologies and Wired-4-Health to improve how healthcare data is shared and used. By joining forces, they can use advanced AI and powerful computing to help healthcare and life sciences organizations deal with data and system challenges more easily and effectively.

    This partnership improves the way transactions are processed, analyzes health outcomes, and ensures compliance, leading to better performance, more reliable data, and a more affordable, scalable system for customers.

    "In the near term, if the healthcare industry expects to succeed in lowering costs while improving quality, the deployment of advanced AI, combined with more powerful, cost- effective compute capabilities will be critical to that success," said Angela Harris, Avant's Chief Operating Officer. "The addition of Wired-4-Health will position Avant as a key contributor in helping healthcare organizations solve complex problems at the intersection of cost, quality, compliance and technology."

    Tech giant Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT) has also been aiding the healthcare sector, most notably with its Azure AI Health Bot, which helps create copilot experiences with healthcare safeguards. Microsoft is enhancing its Azure AI Health Bot services by adding new healthcare-specific safeguards and features, including integration with Microsoft Copilot Studio.

    These upgrades allow healthcare organizations to create their own copilot experiences, with pre-built capabilities, templates, and connectors tailored to healthcare needs, supporting protocol-based workflows alongside AI-based answers, and ensuring compliance with industry standards and guidelines. Now the platform is already being put into use by big players, including by German pharma giant Roche.

    "By leveraging Azure AI Health Bot to build copilot experiences for doctors, we are developing an intuitive, conversational interface that lets clinicians access and explore Roche's clinical documentations in a more natural way and to cope with the complexity and flood of information," said Dr. Georg Isbary of Roche Pharma Germany. "The pilot for this new user experience, powered by generative AI features and compliant with the necessary security standards, has been integrated into our systems and will be further tailored to regional market needs."

    Long-time developer in the AI and machine learning (ML) space for healthcare, Health Catalyst, Inc. (NASDAQ:HCAT) signed a multi-year partnership with SacValley MedShare, one of California's largest and most established qualified health information organization, earlier this year. As per the deal, Health Catalyst will support SacValley's important mission through a broad set of technology solutions, including KPI Ninja by Health Catalyst, Healthcare.AI – a Health Catalyst Data Operating System (DOSTM) Platform module, and several other application solutions and Professional Services.

    "We are honored to partner with SacValley MedShare on their continued journey to advance healthcare and are confident our technology, combined with our dedicated, skilled team members, will deliver the improved efficiency and support SacValley MedShare needs to achieve its healthcare transformation goals," said Dan Burton, CEO of Health Catalyst.

    By choosing Health Catalyst's advanced data and analytics services, SacValley will enhance its ability to share and use information. This will lead to better service for those paying for healthcare, by making it easier to share important health details. This helps in delivering top-notch reports and care for patients.

    "Transforming data from movable to usable is the alchemy of insights, turning raw potential into the gold of informed decision-making, ultimately forging a path towards health equity and improved outcomes," said John Helvey, Executive Director of SacValley MedShare. "This is the primary reason SVMS chose Health Catalyst as a transforming partner."

    Another AI player is Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), which is making it easier and cheaper for other biopharma companies to produce important biological materials and organisms by using artificial intelligence (AI). Back in February 2024, Ginkgo announced the acquisition of key assets of Reverie Labs, which has built and used AI/ML tools to accelerate drug discovery. The acquisition of Reverie's infrastructure and software serves to help train large-scale AI foundation models, while four of Reverie's key AI team members will also be joining Ginkgo.

    Gingko followed this up through a collaboration with UK-based biotech company Prozomix, to build out the production of next generation enzyme plates for active pharmaceutical ingredient (API) manufacturing. The agreement aims to leverage Gingko's Enzyme Services and industry-leading AI/ML models along with Prozomix's existing enzyme libraries and deep experience manufacturing enzyme plates.

    "API manufacturing is poised to greatly benefit from the latest in enzyme engineering and AI/ML enzyme models," said Cindy Chang, Senior Director, Business Development at Ginkgo Bioworks. "We are so excited to partner with Prozomix to get enzymes into as many API routes as possible and help partners meet both their COGs savings and sustainability goals."

    Another developer helping to lead the way in AI-powered healthcare is Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), which uses AI to pick out which treatments should be tested in clinical trials, while also letting biopharma companies to use their AI tools to do so also.

    Last year, Recursion lined up a $50-million collaboration with AI chipmaking giant Nvidia for AI drug discovery. Then at the beginning of 2024, Recursion presented a demonstration of LOWE (Large Language Model-Orchestrated Workflow Engine), a new software designed to perform complex drug discovery tasks using a natural language interface. The platform is powered by Recursion's proprietary biological and chemical data, and can orchestrate experiments using Recursion's automated wet laboratories, unleashing the power of the Recursion Operating System in an easy-to-use tool.

    "For the first time, we've taught Large Language Models to use many of Recursion's tools and data in the same way an expert scientist would, but much more simply and in a more scalable way," said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. "LOWE provides an exciting glimpse into what we believe the future of drug discovery will look like – a first step towards the development of autonomous 'AI scientists' for therapeutic discovery."

    Source:

    https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/

    CONTACT:

    USA News Group

    [email protected]

    604-265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Cision View original content:https://www.prnewswire.com/news-releases/ai-in-healthcare-unveiling-the-future-with-a-42-20-cagr-through-2029--302127333.html

    SOURCE USA News Group

    Get the next $DNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA
    $HCAT
    $MSFT
    $RXRX

    CompanyDatePrice TargetRatingAnalyst
    Health Catalyst Inc
    $HCAT
    8/27/2025$4.00Overweight → Neutral
    Piper Sandler
    Health Catalyst Inc
    $HCAT
    8/11/2025Buy → Neutral
    Citigroup
    Health Catalyst Inc
    $HCAT
    8/8/2025$4.00Overweight → Neutral
    Cantor Fitzgerald
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $675.00Buy
    Jefferies
    Microsoft Corporation
    $MSFT
    7/31/2025$550.00 → $625.00Overweight
    Barclays
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $650.00Overweight
    Wells Fargo
    Microsoft Corporation
    $MSFT
    7/31/2025$585.00 → $640.00Buy
    BofA Securities
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $630.00Outperform
    Oppenheimer
    More analyst ratings

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gibson Christopher converted options into 100,000 shares and sold $476,000 worth of shares (100,000 units at $4.76) (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    9/26/25 6:32:01 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and COO Albert Benjamin was granted 467,000 shares, increasing direct ownership by 421% to 577,870 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    9/26/25 4:25:18 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    New insider Albert Benjamin claimed ownership of 287,765 shares (SEC Form 3)

    3 - Health Catalyst, Inc. (0001636422) (Issuer)

    9/26/25 4:23:43 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

    Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (NASDAQ: MSFT) and Datab

    9/25/25 8:30:00 AM ET
    $MSFT
    $TVGN
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Healthmine Appoints Dwight Erskine as New Chief Executive Officer

    Healthmine, a leading member engagement and rewards platform for health plans, today announced that its Board of Directors has appointed Dwight Erskine as its new Chief Executive Officer, effective September 15, 2025. Erskine succeeds Bryce Williams, who will remain with the company during a transition period before moving into an advisory role. Erskine joins Healthmine as a seasoned leader with more than 25 years of experience in healthcare technology, transformation and analytics. He most recently served as Senior Vice President of Enterprise Transformation at VillageMD where he led the streamlining of clinical operations and scale value-based care delivery across the organization. Prio

    9/24/25 8:30:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Curated for You and Microsoft Launch First-of-Its-Kind AI Fashion Experience in Copilot

    REVOLVE, Steve Madden, Rent the Runway, and Lulus join the platform to bring lifestyle-led discovery to millions AUSTIN, Texas, Sept. 17, 2025 /PRNewswire/ -- Curated for You, the AI-powered lifestyle commerce platform, and Microsoft (NASDAQ:MSFT) today unveiled their breakthrough collaboration, transforming how millions discover fashion. This collaboration officially launches curated fashion discovery in Microsoft Copilot, the everyday AI companion. The new experience is now live, allowing users to discover fashion through natural conversation. Whether you're asking "What sho

    9/17/25 10:55:00 AM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Healthmine Appoints Dwight Erskine as New Chief Executive Officer

    Healthmine, a leading member engagement and rewards platform for health plans, today announced that its Board of Directors has appointed Dwight Erskine as its new Chief Executive Officer, effective September 15, 2025. Erskine succeeds Bryce Williams, who will remain with the company during a transition period before moving into an advisory role. Erskine joins Healthmine as a seasoned leader with more than 25 years of experience in healthcare technology, transformation and analytics. He most recently served as Senior Vice President of Enterprise Transformation at VillageMD where he led the streamlining of clinical operations and scale value-based care delivery across the organization. Prio

    9/24/25 8:30:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Appoints Ben Albert to the Role of President and COO

    Albert Appointed to Drive Health Catalyst Forward in Its Next Chapter of Enabling Measurable Healthcare Improvement SALT LAKE CITY, Sept. 10, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Ben Albert has been appointed as President and Chief Operating Officer. Albert served as the Chief Executive Officer & Co-Founder of Upfront Healthcare Services, Inc. until it was acquired by Health Catalyst in January, and has continued to ov

    9/10/25 4:03:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    $HCAT
    $MSFT
    $RXRX
    SEC Filings

    View All

    SEC Form 8-K filed by Microsoft Corporation

    8-K - MICROSOFT CORP (0000789019) (Filer)

    9/30/25 4:37:10 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Health Catalyst Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Health Catalyst, Inc. (0001636422) (Filer)

    9/10/25 5:20:07 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

    144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/9/25 11:06:59 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Burton Daniel D. bought $204,525 worth of shares (26,200 units at $7.81), increasing direct ownership by 2% to 1,172,623 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    2/27/24 4:01:39 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Health Catalyst downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Health Catalyst from Overweight to Neutral and set a new price target of $4.00

    8/27/25 8:19:35 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst downgraded by Citigroup

    Citigroup downgraded Health Catalyst from Buy to Neutral

    8/11/25 9:56:17 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Health Catalyst from Overweight to Neutral and set a new price target of $4.00

    8/8/25 8:19:52 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Financials

    Live finance-specific insights

    View All

    Microsoft announces quarterly dividend increase

    Annual shareholders meeting set for Dec. 5, 2025 REDMOND, Wash., Sept. 15, 2025 /PRNewswire/ -- Microsoft Corp. on Monday announced that its board of directors declared a quarterly dividend of $0.91 per share, reflecting an 8 cent or 10% increase over the previous quarter's dividend. The dividend is payable Dec. 11, 2025, to shareholders of record on Nov. 20, 2025. The ex-dividend date will be Nov. 20, 2025. In addition, the company announced the date for the 2025 Annual Shareholders Meeting, to be held Dec. 5, 2025. Shareholders at the close of business on Sept. 30, 2025, the

    9/15/25 6:12:00 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Health Catalyst Reports Second Quarter 2025 Results

    SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. "For the second quarter of 2025, I am pleased by our strong financial results, including total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, with these results beating our quarterly guidance on each metric." said Dan Burton, CEO of Health Catalyst. "I also want to share my plan to retire from the CEO role at Health Catalyst effective June 30, 2026. By then, I will have been leading Health Catalyst full-time

    8/7/25 4:03:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $DNA
    $HCAT
    $MSFT
    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Health Catalyst Inc

    SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)

    11/14/24 7:51:57 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Health Catalyst Inc

    SC 13G - Health Catalyst, Inc. (0001636422) (Subject)

    11/14/24 4:44:34 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care